Nantahala Capital Management’s Keros Therapeutics KROS Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15M	Buy	1,360,419 +1,000,000	+277%	+$15.4M	0.94%	49
2025 Q4	$7.34M	Sell	360,419 -872,770	-71%	-$15.3M	0.44%	87
2025 Q3	$19.5M	Sell	1,233,189 -387,503	-24%	-$5.72M	1.2%	31
2025 Q2	$21.6M	Buy	1,620,692 +113,902	+8%	+$1.54M	1.53%	22
2025 Q1	$15.4M	Buy	1,506,790 +591,742	+65%	+$6.87M	1.27%	26
2024 Q4	$14.5M	Buy	915,048 +533,389	+140%	+$27.7M	1.01%	35
2024 Q3	$22.2M	Buy	381,659 +2,852	+0.8%	+$141K	1.86%	19
2024 Q2	$17.3M	Buy	378,807 +84,810	+29%	+$4.56M	1.74%	18
2024 Q1	$19.5M	Sell	293,997 -16,144	-5%	-$957K	1.91%	19
2023 Q4	$12.3M	Sell	310,141 -18,640	-6%	-$584K	1.23%	25
2023 Q3	$10.5M	Sell	328,781 -168,380	-34%	-$6.29M	1.33%	25
2023 Q2	$20M	Sell	497,161 -245,658	-33%	-$10.8M	2.42%	10
2023 Q1	$31.7M	Sell	742,819 -49,274	-6%	-$2.49M	3.04%	10
2022 Q4	$38M	Sell	792,093 -53,599	-6%	-$2.5M	3.44%	9
2022 Q3	$31.8M	Sell	845,692 -66,209	-7%	-$2.29M	3.12%	12
2022 Q2	$25.2M	Buy	911,901 +95,071	+12%	+$4.17M	2.18%	23
2022 Q1	$44.4M	Buy	816,830 +20,132	+3%	+$1.03M	3.07%	14
2021 Q4	$46.6M	Buy	796,698 +36,315	+5%	+$1.81M	2.9%	18
2021 Q3	$30.1M	Buy	760,383 +161,503	+27%	+$5.75M	1.78%	30
2021 Q2	$25.4M	Buy	598,880 +138,508	+30%	+$7.5M	1.4%	33
2021 Q1	$28.3M	Sell	460,372 -74,142	-14%	-$4.7M	1.61%	31
2020 Q4	$37.7M	Buy	534,514 +257,687	+93%	+$16.2M	1.95%	21
2020 Q3	$10.7M	Buy	276,827 +1,827	+0.7%	+$72.5K	0.71%	64
2020 Q2	$10.3M	Buy	+275,000	New	+$8.47M	0.67%	61